anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:The compound of formula I (R<1> and R<2> are lower alkyl; n is 0-2). EXAMPLE:2-[(1-methyl-1,2,3,4-tetrazol-5-yl)thio]acetic acid methyl ester. USE:A radiation sensitizer to increase the radiation sensitivity of intercalary hypoxic tumor cell of phyma. It has excellent transferability between tissues and solubility in water, high resistance to inactivation by metabolism, and low side effects. PREPARATION:The compound of formula I (sulfide derivative) wherein n is 0 can be produced by reacting the mercaptotetrazole derivative of formula II (M is H or alkali metal) with the acetic acid derivative of formula III in a solvent such as alcohol, ether, etc. at 10-60 deg.C. The obtained sulfide derivative is oxidized with 1-1.5 equivalent of oxidizing agent to obtain a sulfoxide derivative (n=1) or with 2-4 equivalent of oxidizing agent to afford a sulfone derivative (n=2).
Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
1318259 Administering medicaments to ruminants COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGANISATION 28 Aug 1970 [28 Aug 1969] 41551/70 Headings A5B and A5R Apparatus for administering a therapeutic or a nutrient substance to a ruminant comprises a device, of or containing said substance, which is adapted to be arranged in a first configuration to be passed through the mouth of the animal, and then to assume a second configuration to prevent or hinder regurgitation of the device. In the embodiment shown, two generally semi-cylindrical members 1, closed at their ends, are hinged at 9A, 8B, and a band 14 of elastic material is attached at the outsides of the members, as shown, and passes through a member 13 attached to both members 1 along their common edge and bent into the shape of a "U". In use a substance in liquid form is placed into each member I via the slots 4 and the members are united to form a generally, closed cylindrical shape and thus retained, against the tension in the band 14, by a band of material, e.g. gelatin, soluble in the environment inside an animal, which upon dissolving allows the device to assume the configuration shown to hinder regurgitation and liberate the substance to the animal tissue. The hinges 9A, 8B and the band 14 are made from or secured to components of a material which is either soluble or frangible in the stomach of the animal so that the device may break into separate components for regurgitation after all the medicant substance has been exhausted. Other embodiments described all preferably being bound by a soluble gelatin band prior to insertion, comprise two closed semi-cylinders (21), Fig. 4 (not shown), bound together by strips (22) of material comprising a layer of hyrophobic substance and a layer of hydrophilic substance, which strip is adapted to hold the members (21) at a distance in the animal. A further embodiment, Fig. 6 (not shown) comprises two similar semi-cylinders (31) attached by a resilient nylon hinge (32). Projections (42), (43), Fig. 8 (not shown) may be employed, or a resilient device of toroidal shape, Fig. 10 (not shown) may be restrained by soluble gelatin bands (52) prior to insertion. A large number of materials and medicaments are mentioned, a preferred medicament substance being a bloat control agent, e.g. a polyoxyalkylene, which is preferably contained in a matrix of a gel having ethyl cellulose as gelling agent. Alternatively the substance may be a source of magnesium.
D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29 to D78 received continuous subcutaneous abdominal injections of 2.4 mg of JY09 injection in the morning, once weekly (total of 8 administrations). All doses were to be administered within 3 min.
PURPOSE: A complex cultivating method of Chaga mushroom, Phellinus baumii, Ganoderma lucidum, Blossom mushroom, and Cordyceps is provided to mass-produce the complex culture mycelia of blossom mushroom, Ganoderma lucidum, and Cordyceps and is provided for medical supplies and functional foods such as anticancer. CONSTITUTION: A step(first process) of finely comminuting after drying more than one kind of mushrooms selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom; a step(second process) of manufacturing medium by controlling the moisture of the mushroom powder which is selected from one kind of mushroom from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom to 20-60% and sterilizing; and a step(third process) of cultivating by engrafting medium containing more than one kind of mushroom selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom manufactured in second process by respectively aseptic processing Chaga mushroom, Phellinus baumii, Ganoderma lucidum, Blossom mushroom, and Cordyceps at 20-40°C for 15-50 days is comprised. In the third process, inoculate Chaga mushroom, Phellinus baumii, Ganoderma lucidum, Blossom mushroom, and Cordyceps respectively by 0.1-1 parts by weight to medium 100 parts by weight containing more than one kind of mushroom selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom. In the third process, instead of inoculating to the medium which contains more than one kind of mushroom selected from Chaga mushroom, Phellinus baumii, Ganoderma lucidum, Blossom mushroom, and Cordyceps, inoculate complex culture mycelia of these 5 kinds of mushrooms to the medium which contains more than one kind of mushroom selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom. Inoculate 0.5-5 parts by weight of complex culture mycelia with the five kinds of mushrooms to the medium containing more than one kind of mushroom selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom based on the medium of 100 parts by weight containing more than one kind of mushroom selected from Shiitake mushroom, Blossom mushroom, and Agaricus mushroom. Complex culture mycelia of five kinds of mushrooms is manufactured and cultivated at 20-40°C for 15-50 days by inoculating Chaga mushroom of 0.1-1 parts by weight, Phellinus baumii of 0.1-1 parts by weight, Ganoderma lucidum of 0.1-1 parts by weight, Blossom mushroom of 0.1-1 parts by weight and Cordyceps of 0.1-1 parts by weight at the same time based on grain medium of 100 parts by weight. [Reference numerals] (AA) (first process) step of finely comminuting after drying Shiitake mushroom; (BB) (second process) step of manufacturing mushroom media by controlling the moisture of the shiitake mushroom powder from the first process to 20-60% and sterilizing; (CC) (third process) step of asepsis treating the complex mycelial culture extract of Chaga mushroom, Phellinus linteus, Ganoderma lucidum, Sparassis crispa Wulf., and Cordyceps, inoculating to the Shiitake mushroom media, and cultivating at 20-40 for 15-50 days
The instant invention describes the production of neoglycans, compounds capable of inhibiting tumor cell growth. The heparan sulfate proteoglycan syndecan-1 is a tumor suppressor molecule that inhibits growth and induces apoptosis in several cancer cell lines. Attempts to create synthetic analogues of syndecan-1 by carbodiimide (EDAC) conjugation of a protein scaffold and GAG surprisingly revealed that the protein component is not required. Neoglycans consisting of EDAC-modified heparin and EDAC-modified chondroitin sulfate (CS), respectively named neoheparin and neo-chondroitin sulfate (neoCS), were found to inhibit multiple myeloma cell viability. Further analysis revealed the neoglycan compounds severely reduced cell viability of multiple myeloma, breast cancer and normal laboratory cell lines and peripheral blood mononuclear cells through the induction of apoptosis. Neoglycans provide a new class of GAG chain-based anticancer therapeutics.
OBREDON contains hydrocodone, a Schedule II controlled substance. As an opioid, OBREDON exposes users to the risks of addiction, abuse, and misuse [ see Drug Abuse and Dependence ( 9) ], which can lead to overdose and death [ see Overdosage ( 10) ]. Reserve OBREDON for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient’s risk prior to prescribing OBREDON, prescribe OBREDON for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addiction or abuse, and refill only after reevaluation of the need for continued treatment.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OBREDON. Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing OBREDON. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [ see Patient Counseling Information ( 17) ]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
The ketogenic diet is a high-fat, moderate protein, low-carbohydrate diet. It is an internationally established treatment option in children with drug resistant epilepsy. About 40 -70 % of children with drug resistant epilepsy treated with the ketogenic diet achieve \> 50 % seizure reduction. However, even though the ketogenic diet has been used in the treatment of epilepsy for almost a Century, little is known about how the dietary treatment reduces seizures and which patients that will respond well. In addition, there is limited knowledge about potential adverse effects of the treatment. This is a prospective study following the patients from 4 weeks before initiating the ketogenic diet and during the treatment. The influence of the dietary treatment on the gut microbiota, epigenetics, quality of life, and adverse effects will be investigated.
Approximately 80 subjects will be randomized by computer to receive equally either sham therapy or plasma / nitric oxide treatments topically. The nitric oxide / plasma treatment will be delivered from 11.5 to 15 centimeters from the wound surface for 10 seconds per cm2 of wound size. Subjects will be evaluated for efficacy and safety on a regular basis with clinical observations. The wounds of both groups will be treated with sharp debridement as determined by the site Investigator. A collagen dressing, a non-adherent dressing, and an absorptive dressing will be applied to the wound after either the study therapy or the sham therapy.

For an initial safety evaluation in patients with DFU, the first ten patients randomized will be limited to wound size of 7 cm2 or less and their wounds will be assessed 2-4 days after each treatment session. Following completion of the final assessment in these 10 patients, data will be submitted to FDA for review and approval before opening the enrolment for the remaining patients.
The following adverse reactions have been identified during post approval use of fluoxetine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.

Voluntary reports of adverse reactions temporally associated with fluoxetine that have been received since market introduction and that may have no causal relationship with the drug include the following: aplastic anemia, atrial fibrillation1, cataract, cerebrovascular accident1, cholestatic jaundice, dyskinesia (including, for example, a case of buccal-lingual-masticatory syndrome with involuntary tongue protrusion reported to develop in a 77-year-old female after 5 weeks of fluoxetine therapy and which completely resolved over the next few months following drug discontinuation), eosinophilic pneumonia1, epidermal necrolysis, erythema multiforme, erythema nodosum, exfoliative dermatitis, gynecomastia, heart arrest1, hepatic failure/necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, kidney failure, memory impairment, movement disorders developing in patients with risk factors including drugs associated with such reactions and worsening of pre-existing movement disorders, optic neuritis, pancreatitis1, pancytopenia, pulmonary embolism, pulmonary hypertension, QT prolongation, Stevens-Johnson syndrome, thrombocytopenia1, thrombocytopenic purpura, ventricular tachycardia (including Torsades de Pointes–type arrhythmias), vaginal bleeding, and violent behaviors1.

1.
    These terms represent serious adverse events, but do not meet the definition for adverse drug reactions. They are included here because of their seriousness.
Treatment consists of appropriate supportive measures. The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. Gastric contents may be evacuated by gastric lavage as indicated. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.

Efficacy of peritoneal dialysis or extracorporeal hemodialysis for METADATE CD overdosage has not been established.

The prolonged release of methylphenidate from METADATE CD should be considered when treating patients with overdose.
The present invention relates to an iodizing method for drinking water and a device thereof. The present invention is mainly characterized in that resin with iodine is used as an iodine release preparation for replenishing iodine for drinking water, and the iodine release preparation is sealed in a device which is in a microporous structure; so water flows across the device, or the device is directly soaked in a water storage container, and iodine ions can be quickly, enduringly and uniformly released in the water. The iodizing method is simple and convenient to enforce. The iodizing device is easy to manufacture and use. Tests and observation in regions with iodine deficiency disorders show that the present invention has significant effect on replenishing iodine for human bodies and preventing and treating iodine deficiency disorders. The present invention has practical significance in controlling and eliminating the iodine deficiency disorders in remote mountain areas and remote countries.
Anemia is common in patients with rheumatoid arthritis (RA), and it is unknown whether the dietary inflammatory index (DII) is linked to anemia. This study aimed to clarify the prevalence of anemia in RA patients and its association with the DII. The data utilized in this study were collected from the National Health and Nutrition Examination Survey database from 1999 to 2018. The prevalence of anemia in RA patients was estimated by ethnicity, sex, and age. Weighted multivariate logistic regression was utilized to explore the correlation between anemia risk and DII. The most crucial dietary factors related to the risk of anemia in RA patients were screened by stepwise regression. A nomogram model was established according to key dietary factors. A total of 10.25% (confidence interval, 8.58-11.92%) of RA patients will develop anemia, with the lowest prevalence around the age of 60. In addition, higher DII levels were discovered in anemic patients than in nonanemic patients. In multivariate regression models, an important positive association was revealed between anemia and growing quartiles of DII (Q4 vs Q1: odds ratio = 1.98; confidence interval, 1.25-3.15). In the subgroup analysis, the adjusted relation of DII with anemia in females, Mexicans, smokers, nondrinkers, and age groups ≥ 60 years was statistically significant. The same association was observed in the sensitivity analysis. A nomogram model based on stepwise regression screening of key dietary factors showed good discriminatory power to identify anemic risk in RA patients (area under the curve: 0.707). In patients with RA, high DII levels were associated with the risk of anemia. More attention should be given to controlling dietary inflammation to better prevent and treat anemia.
In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST.
BACKGROUND: Liver damage from nonalcoholic steatohepatitis (NASH) presents a significant challenge to the health and productivity of ruminants. However, the regulatory mechanisms behind variations in NASH susceptibility remain unclear. The gut‒liver axis, particularly the enterohepatic circulation of bile acids (BAs), plays a crucial role in regulating the liver diseases. Since the ileum is the primary site for BAs reabsorption and return to the liver, we analysed the ileal metagenome and metabolome, liver and serum metabolome, and liver single-nuclei transcriptome of NASH-resistant and susceptible goats together with a mice validation model to explore how ileal microbial BAs metabolism affects liver metabolism and immunity, uncovering the key mechanisms behind varied NASH pathogenesis in dairy goats.
RESULTS: In NASH goats, increased total cholesterol (TC), triglyceride (TG), and primary BAs and decreased secondary BAs in the liver and serum promoted hepatic fat accumulation. Increased ileal Escherichia coli, Erysipelotrichaceae bacterium and Streptococcus pneumoniae as well as proinflammatory compounds damaged ileal histological morphology, and increased ileal permeability contributes to liver inflammation. In NASH-tolerance (NASH-T) goats, increased ursodeoxycholic acid (UDCA), isodeoxycholic acid (isoDCA) and isolithocholic acid (isoLCA) in the liver, serum and ileal contents were attributed to ileal secondary BAs-producing bacteria (Clostridium, Bifidobacterium and Lactobacillus) and key microbial genes encoding enzymes. Meanwhile, decreased T-helper 17 (TH17) cells and increased regulatory T (Treg) cells proportion were identified in both liver and ileum of NASH-T goats. To further validate whether these key BAs affected the progression of NASH by regulating the proliferation of TH17 and Treg cells, the oral administration of bacterial UDCA, isoDCA and isoLCA to a high-fat diet-induced NASH mouse model confirmed the amelioration of NASH through the TH17 cell differentiation/IL-17 signalling/PPAR signalling pathway by these bacterial secondary BAs.
CONCLUSION: This study revealed the roles of ileal microbiome and its secondary BAs in resilience and susceptibility to NASH by affecting the hepatic Treg and TH17 cells proportion in dairy goats. Bacterial UDCA, isoDCA and isoLCA were demonstrated to alleviate NASH and could be novel postbiotics to modulate and improve the liver health in ruminants. Video Abstract.
An infant was admitted with suspected postinfectious malabsorption with watery diarrhoea, fever and failure to thrive. She had dehydration, acute kidney injury and metabolic acidosis, which were corrected with intravenous fluids and managed with empiric antibiotics and prophylactic antifungals. She also developed Escherichia coli sepsis, meningitis and Candida skin infections during hospitalisation, which were treated according to the culture reports. Intrauterine growth restriction, woolly hair and a broad nasal bridge with chronic refractory diarrhoea prompted genetic testing to rule out syndromic diarrhoea. Whole-exome sequencing revealed a pathogenic compound heterozygous mutation causing trichohepatoenteric syndrome. She succumbed to severe infections at 80 days of life. The condition is rare, and no established guidelines or specific treatments exist; the focus is to promote optimal growth through parenteral nutrition, elemental formula and infection control. Early suspicion and molecular genetic testing can help reduce the time to diagnosis, treatment and genetic counselling.
OBJECTIVE: Sudden unexpected death in epilepsy (SUDEP) is an underestimated complication of epilepsy. Previous studies have demonstrated that enhancement of serotonergic neurotransmission suppresses seizure-induced sudden death in evoked seizure models. However, it is unclear whether elevated serotonin (5-HT) function will prevent spontaneous seizure-induced mortality (SSIM), which is characteristic of human SUDEP. We examined the effects of 5-HT-enhancing agents that act by three different pharmacological mechanisms on SSIM in Dravet mice, which exhibit a high incidence of SUDEP, modeling human Dravet syndrome.
METHODS: Dravet mice of both sexes were evaluated for spontaneous seizure characterization and changes in SSIM incidence induced by agents that enhance 5-HT-mediated neurotransmission. Fluoxetine (a selective 5-HT reuptake inhibitor), fenfluramine (a 5-HT releaser and agonist), SR 57227 (a specific 5-HT3 receptor agonist), or saline (vehicle) was intraperitoneally administered over an 8-day period in Dravet mice, and the effect of these treatments on SSIM was examined.
RESULTS: Spontaneous seizures in Dravet mice generally progressed from wild running to tonic seizures with or without SSIM. Fluoxetine at 30 mg/kg, but not at 20 or 5 mg/kg, significantly reduced SSIM compared with the vehicle control. Fenfluramine at 1-10 mg/kg, but not .2 mg/kg, fully protected Dravet mice from SSIM, with all mice surviving. Compared with the vehicle control, SR 57227 at 20 mg/kg, but not at 10 or 5 mg/kg, significantly lowered SSIM. The effect of these drugs on SSIM was independent of sex.
SIGNIFICANCE: Our data demonstrate that elevating serotonergic function by fluoxetine, fenfluramine, or SR 57227 significantly reduces or eliminates SSIM in Dravet mice in a sex-independent manner. These findings suggest that deficits in serotonergic neurotransmission likely play an important role in the pathogenesis of SSIM, and fluoxetine and fenfluramine, which are US Food and Drug Administration-approved medications, may potentially prevent SUDEP in at-risk patients.
<P>PROBLEM TO BE SOLVED: To provide composite powder which reinforces the effect of interference light, and is excellent in effects for enhancing transparency and for making three-dimensional appearances prominent, when compounded with cosmetics.  <P>SOLUTION: Provided is the composite powder prepared by coating flaky glass substrates having interference light with Black No.401. It is preferable that the Black No.401 is Black No.401 adhered to hydrotalcite type laminar compound oxide inorganic flake particles. It is preferable that the flaky glass substrates having interference light are glass substrates prepared by disposing titanium dioxide layers on flaky glass substrates. It is preferable that the flaky glass substrates have an average particle diameter of 10 to 4,000 μm, a thickness of 0.01 to 20 μm, and an aspect ratio (major axis/thickness) of 1 to 200. The content of Black No.401 in the composite powder is preferably 1 to 3%. A cosmetic contains the composite powder. The cosmetic is preferably a make-up cosmetic.  <P>COPYRIGHT: (C)2009,JPO&INPIT